**Author details**

Michael Meisenheimer1 \*, Yury Saenko2 and Elisabeth Eppard3 \*

1 Department of Nuclear Medicine, University Hospital Bonn, Germany

2 S.P. Kapitsa Research Institute of Technology, Ulyanovsk State University, Ulyanovsk, Russia

3 Positronpharma SA, Providencia, Chile

\*Address all correspondence to: michael.meisenheimer@ukbonn.de and eeppard@positronpharma.cl

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**39**

*Gallium-68: Radiolabeling of Radiopharmaceuticals for PET Imaging - A Lot to Consider*

with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509). Annals of

[8] Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study. European Journal of Nuclear Medicine and Molecular Imaging.

[9] Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Annals of Oncology. 2013;**24**(1):152-160

[10] Gleason GI. A positron cow. The International Journal of Applied Radiation and Isotopes.

[11] Breeman WAP, Jong M,

[12] Velikyan I, Beyer GJ,

2004;**31**(8):1097-1104

Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTApeptides with 68Ga. European Journal of Nuclear Medicine and Molecular Imaging. 2005;**32**(4):478-485

Langström B. Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity. Bioconjugate

[13] Meyer G-J, Mäcke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. European Journal of Nuclear Medicine and Molecular Imaging.

[14] Lenzo NP, Meyrick D, Turner JH. Review of Gallium-68 PSMA PET/CT

Chemistry. 2004;**15**(3):554-560

1960;**8**(2-3):90-94

Oncology. 2018;**29**(suppl\_8)

2011;**38**(12):2125-2135

*DOI: http://dx.doi.org/10.5772/intechopen.90615*

Herrmann K. 68Gallium- and 90Yttrium−/ 177Lutetium: "Theranostic twins" for diagnosis and treatment of NETs. Annals of Nuclear Medicine.

[2] Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. Health-related quality of life in patients with progressive Midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial. Journal of Clinical Oncology. 2018;**36**(25):2578-2584

[3] Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for Midgut neuroendocrine tumors. The New England Journal of Medicine.

Molecular Imaging. 2014;**41**(10):1845-1851

[5] Mahajan S, O'Donoghue J, Weber W, Bodei L. Integrating early rapid postpeptide receptor radionuclide therapy quality assurance scan into the outpatient setting. Journal of Nuclear Medicine and Radiation Therapy. 2019;**10**(1):395

Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study. Endocrine-Related Cancer. 2019;**26**(2):227-239

[7] Capdevila J, Fazio N, Lopez C, Teule A, Valle JW, Tafuto S, et al. 1307OEfficacy of lenvatinib in patients

**References**

2015;**29**(1):1-7

2017;**376**(2):125-135

[4] Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E, et al. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: Results from a phase II study. European Journal of Nuclear Medicine and

[6] Carlsen EA, Fazio N,

[1] Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, *Gallium-68: Radiolabeling of Radiopharmaceuticals for PET Imaging - A Lot to Consider DOI: http://dx.doi.org/10.5772/intechopen.90615*
